Xiangyu Xu Zixia Shi Dan Fu Depei Huang Zheng Ma
10.3389/fonc.2022.1008932
Front Oncol
2022 Oct 19;12:1008932.
epidermal growth factor receptor (egfr) lung squamous cell carcinoma mutations neoadjuvant immunotherapy pembrolizumab programmed death ligand-1 (pd-l1)
CC BY
https://pubmed.ncbi.nlm.nih.gov/36338754/
Case Reports
PMC9627657
36338754
EGFR mutations and high PD-L1 expression of lung squamous cell carcinoma patients achieving pCR following neoadjuvant immuno-chemotherapy: Case report
2022